Premium
T‐cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis
Author(s) -
Dubal Dena B.,
Mueller Sabine,
Ruben Beth S.,
Engstrom John W.,
Josephson S. Andrew
Publication year - 2009
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21306
Subject(s) - myasthenia gravis , mycophenolate , medicine , prednisone , adverse effect , complication , mycophenolic acid , post transplant lymphoproliferative disorder , lymphoproliferative disorders , dermatology , immunosuppressive drug , immunology , gastroenterology , surgery , transplantation , lymphoma , rituximab
Immunosuppressive therapies are critical in the management of numerous conditions including myasthenia gravis. Mycophenolate mofetil is a widely used, oral immunosuppressive agent that is considered to have few adverse effects compared with similar drugs. We report the case of a patient who developed T‐cell lymphoproliferative lesions following long‐term treatment with mycophenolate mofetil and prednisone for myasthenia gravis. The lesions resolved following cessation of the treatment. This case highlights a serious complication of a commonly used drug. Muscle Nerve, 2009